Title: NOVEL 3-AZA-SPIRO[5.5]UNDECANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSmitter RE-UPTAKE INHIBITORS

Abstract: This invention relates to novel 3-aza-spiro[5.5]undecane derivatives useful as monoamine neurotransmitter re-uptake inhibitors. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.
NOVEL 3-AZA-SPIRO[S-S]UNDECANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS

TECHNICAL FIELD

This invention relates to novel 3-aza-spiro[5.5]undecane derivatives useful as monoamine neurotransmitter re-uptake inhibitors.

In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.

BACKGROUND ART

Serotonin Selective Reuptake Inhibitors (SSRIs) currently provide efficacy in the treatment of several CNS disorders, including depression and panic disorder. SSRIs are generally perceived by psychiatrists and primary care physicians as effective, well-tolerated and easily administered. However, they are associated with a number of undesirable features.

Thus, there is still a strong need for compounds with an optimised pharmacological profile as regards the activity on reuptake of the monoamine neurotransmitters serotonin, dopamine and noradrenaline, such as the ratio of the serotonin reuptake versus the noradrenaline and dopamine reuptake activity.

SUMMARY OF THE INVENTION

In its first aspect, the invention provides a compound of Formula I:

\[
\begin{array}{c}
\text{R}^a \text{N} \\
\text{X} \\
\text{R}^b
\end{array}
\]

any of its isomers or any mixture of its isomers, or a pharmaceutically acceptable salt thereof,

wherein \( \text{R}^a, \text{R}^b \) and \( \text{X} \) are as defined below.

In its second aspect, the invention provides a pharmaceutical composition, comprising a therapeutically effective amount of a compound of the invention, any of
its isomers or any mixture of its isomers, or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, excipient or diluent.

In a further aspect, the invention provides the use of a compound of the invention, any of its isomers or any mixture of its isomers, or a pharmaceutically acceptable salt thereof, for the manufacture of a pharmaceutical composition for the treatment, prevention or alleviation of a disease or a disorder or a condition of a mammal, including a human, which disease, disorder or condition is responsive to inhibition of monoamine neurotransmitter re-uptake in the central nervous system.

In a still further aspect, the invention relates to a method for treatment, prevention or alleviation of a disease or a disorder or a condition of a living animal body, including a human, which disorder, disease or condition is responsive to inhibition of monoamine neurotransmitter re-uptake in the central nervous system, which method comprises the step of administering to such a living animal body in need thereof a therapeutically effective amount of a compound of the invention, any of its isomers or any mixture of its isomers, or a pharmaceutically acceptable salt thereof.

Other objects of the invention will be apparent to the person skilled in the art from the following detailed description and examples.

DETAILED DISCLOSURE OF THE INVENTION

3-aza-spiro[5.5]undecane derivatives

In its first aspect the present invention provides compounds of formula I:

\[
\text{R}^a - \text{N} - \text{X} - \text{R}^b
\]

any of its isomers or any mixture of its isomers, or a pharmaceutically acceptable salt thereof;

wherein

\text{R}^a\text{ represents }\text{hydrogen or alkyl;}

\text{which alkyl is optionally substituted with one or more substituents independently selected from the group consisting of:}

\text{halo, trifluoromethyl, trifluoromethoxy, cyano, hydroxy, amino, nitro, alkoxy, cycloalkoxy, alkyl, cycloalkyl, cycloalkylalkyl, alkenyl and alkynyl; and}

\text{R}^b\text{ represents an aryl or a heteroaryl group;}

\text{which aryl or heteroaryl group is optionally substituted with one or more substituents independently selected from the group consisting of:}
halo, trifluoromethyl, trifluoromethoxy, cyano, nitro, hydroxy, alkoxy, cycloalkoxy, alkoxyalkyl, cycloalkoxyalkyl, methylenedioxy, ethylenedioxy, alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, -NR'R", -(C=O)NR'R" or -NR'(C=O)R";

wherein R' and R" independent of each other are hydrogen or alkyl

X represents -O- or -NR C ;

wherein R C represents hydrogen or alkyl.

In one embodiment, R a represents hydrogen or alkyl. In a special embodiment, R a represents hydrogen. In a further embodiment, R a represents alkyl, such as methyl.

In a still further embodiment, R b represents a phenyl group, which phenyl group is optionally substituted with one or more substituents independently selected from the group consisting of: halo, trifluoromethyl, trifluoromethoxy, cyano and alkoxy.

In a further embodiment, R b represents a phenyl group, which phenyl group is substituted once or twice with substituents independently selected from the group consisting of: halo, trifluoromethyl, trifluoromethoxy, cyano and alkoxy.

In a special embodiment, R b represents halophenyl, such as chlorophenyl, such as 4-chlorophenyl. In a further embodiment, R b represents dihalophenyl, such as 3,4-dihalophenyl. In a still further embodiment, R b represents dichlorophenyl, such as 3,4-dichlorophenyl.

In a further embodiment, R b represents bromo-chlorophenyl, such as 3-bromo-4-chloro-phenyl. In a still further embodiment, R b represents chloro-fluorophenyl, such as 3-chloro-4-fluoro-phenyl or 4-chloro-3-fluoro-phenyl. In a further embodiment, R b represents halo-trifluoromethyl-phenyl, such as chloro-trifluoromethyl-phenyl, such as 4-chloro-3-trifluoromethyl-phenyl.

In a still further embodiment, R b represents a naphthyl group, which naphthyl group is optionally substituted with one or more substituents independently selected from the group consisting of: halo, trifluoromethyl, trifluoromethoxy, cyano and alkoxy.

In a special embodiment, R b represents naphthyl. In a further embodiment, R b represents alkoxynaphthyl, such as methoxynaphthyl, such as 6-methoxy-naphthalen-2-yl.

In a still further embodiment, R b represents an optionally substituted coumarinyl group. In a special embodiment, R b represents coumarinyl, such as coumarin-6-yl or coumarin-7-yl.

In a further embodiment, X represents -O-. In a still further embodiment, X represents -NR C . In a further embodiment R c represents hydrogen. In a special embodiment, X represents -O- or -NH-.

In a special embodiment the compound of the invention is 9-(3,4-Dichloro-phenoxy)-3-aza-spiro[5.5]undecane;
9-(6-Methoxy-naphthalen-2-yloxy)-3-aza-spiro[5.5]undecane; 
7-(3-Aza-spiro[5.5]undec-9-yloxy)-chromen-2-one; 
9-(3-Bromo-4-chloro-phenoxy)-3-aza-spiro[5.5]undecane; 
9-(4-Chloro-phenoxy)-3-aza-spiro[5.5]undecane; 
5 9-(4-Chloro-3-fluoro-phenoxy)-3-aza-spiro[5.5]undecane; 
9-(3-Chloro-4-fluoro-phenoxy)-3-aza-spiro[5.5]undecane; 
9-(4-Chloro-3-fluoro-phenoxy)-3-aza-spiro[5.5]undecane; 
9-(4-Chloro-phenoxy)-3-aza-spiro[5.5]undecane; 
6 9-(3,4-Dichloro-phenoxy)-3-methyl-3-aza-spiro[5.5]undecane; 
9-(Naphthalen-2-yloxy)-3-aza-spiro[5.5]undecane; 
9-(6-Methoxy-naphthalen-2-yloxy)-3-aza-spiro[5.5]undecane; 
9-(3-aza-spiro[5.5]undec-9-yloxy)-chromen-2-one; 
9-(3-Bromo-4-chloro-phenoxy)-3-aza-spiro[5.5]undecane; 
9-(3-Chloro-4-fluoro-phenoxy)-3-aza-spiro[5.5]undecane; 
9-(3-Chloro-4-chloro-phenoxy)-3-aza-spiro[5.5]undecane; 
9-(4-Chloro-phenoxy)-3-aza-spiro[5.5]undecane; 
9-(3,4-Dichloro-phenoxy)-3-methyl-3-aza-spiro[5.5]undecane; 
or a pharmaceutically acceptable salt thereof.

Any combination of two or more of the embodiments as described above is considered within the scope of the present invention.

**Definition of Substituents**

In the context of this invention halo represents fluoro, chloro, bromo or iodo.

In the context of this invention an alkyl group designates a univalent saturated, straight or branched hydrocarbon chain. The hydrocarbon chain preferably contains of from one to six carbon atoms (Ci₆-alkyl), including pentyl, isopentyl, neopentyl, tertiary pentyl, hexyl and isohexyl. In a preferred embodiment alkyl represents a Ci-4-alkyl group, including butyl, isobutyl, secondary butyl, and tertiary butyl. In another preferred embodiment of this invention alkyl represents a di-3-alkyl group, which may in particular be methyl, ethyl, propyl or isopropyl.

In the context of this invention an alkenyl group designates a carbon chain containing one or more double bonds, including di-enes, tri-enes and poly-enes. In a preferred embodiment the alkenyl group of the invention comprises of from two to six carbon atoms (C₂-₆-alkenyl), including at least one double bond. In a most preferred embodiment the alkenyl group of the invention is ethenyl; 1- or 2-propenyl; 1-, 2- or 3-butenyl, or 1,3-butadienyl; 1 -, 2-, 3-, 4- or 5-hexenyl, or 1,3-hexadienyl, or 1,3,5-hexatrienyl.

In the context of this invention an alkynyl group designates a carbon chain containing one or more triple bonds, including di-yenes, tri-yenes and poly-yenes. In a preferred embodiment the alkynyl group of the invention comprises of from two to six carbon atoms (C₂-₆-alkynyl), including at least one triple bond. In its most preferred embodiment the alkynyl group of the invention is ethynyl; 1-, or 2-propynyl; 1-, 2-, or 3-butynyl, or 1,3-butadiynyl; 1-, 2-, 3-, 4-pentylnyl, or 1,3-pentadiynyl; 1-, 2-, 3-, 4-, or 5-hexynyl, or 1,3-hexadiynyl or 1,3,5-hexatriynyl.
In the context of this invention a cycloalkyl group designates a cyclic alkyl group, preferably containing from three to seven carbon atoms (C₃₋₋₋₇-cycloalkyl), including cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.

Alkoxy is O-alkyl, wherein alkyl is as defined above.

Cycloalkoxy means O-cycloalkyl, wherein cycloalkyl is as defined above.

Cycloalkylalkyl means cycloalkyl as above and alkyl as above, meaning for example, cyclopropylmethyl.

In the context of this invention an aryl group designates a carbocyclic aromatic ring system such as phenyl, napthyl or fluorenyl.

In the context of this invention a heteroaryl group designates an aromatic mono- or bicyclic heterocyclic group, which holds one or more heteroatoms in its ring structure. Preferred heteroatoms include nitrogen (N), oxygen (O), and sulphur (S).

Preferred monocyclic heteroaryl groups of the invention include aromatic 5- and 6-membered heterocyclic groups, including for example, but not limited to, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, tetrazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, triazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, imidazolyl, pyrrolyl, pyrazolyl, furanyl, thienyl, pyridyl, pyrimidyl, or pyridazinyl.

Preferred bicyclic heteroaryl groups of the invention include for example, but not limited to, indolizinyl, indolyl, isoindolyl, indazolyl, benzofuranyl, benzo[b]thienyl, benzimidazolyl, benzoazole, benzoxadiazole, benzothiazolyl, benzo[d]isothiazolyl, purinyl, quinolinyl, isoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 1,8-naphthyridinyl, pteridinyl, and indenyl. Included in the bicyclic heteroaryl group is also coumarinyl.

Pharmaceutically Acceptable Salts

The chemical compound of the invention may be provided in any form suitable for the intended administration. Suitable forms include pharmaceutically (i.e. physiologically) acceptable salts, and pre- or prodrug forms of the chemical compound of the invention.

Examples of pharmaceutically acceptable addition salts include, without limitation, the non-toxic inorganic and organic acid addition salts such as the hydrochloride, the hydrobromide, the nitrate, the perchlorate, the phosphate, the sulphate, the formate, the acetate, the aconate, the ascorbate, the benzenesulphonate, the benzoate, the cinnamate, the citrate, the embonate, the enantate, the fumarate, the glutamate, the glycolate, the lactate, the maleate, the malonate, the mandelate, the methanesulphonate, the naphthalene-2-sulphonate, the phthalate, the salicylate, the sorbate, the stearate, the succinate, the tartrate, the toluene-p-sulphonate, and the like. Such salts may be formed by procedures well known and described in the art.
Other acids such as oxalic acid, which may not be considered pharmaceutically acceptable, may be useful in the preparation of salts useful as intermediates in obtaining a chemical compound of the invention and its pharmaceutically acceptable acid addition salt.

Examples of pharmaceutically acceptable cationic salts of a chemical compound of the invention include, without limitation, the sodium, the potassium, the calcium, the magnesium, the zinc, the aluminium, the lithium, the choline, the lysinium, and the ammonium salt, and the like, of a chemical compound of the invention containing an anionic group. Such cationic salts may be formed by procedures well known and described in the art.

In the context of this invention the "onium salts" of N-containing compounds are also contemplated as pharmaceutically acceptable salts. Preferred "onium salts" include the alkyl-onium salts, the cycloalkyl-onium salts, and the cycloalkylalkyl-onium salts.

Examples of pre- or prodrug forms of the chemical compound of the invention include examples of suitable prodrugs of the substances according to the invention include compounds modified at one or more reactive or derivatizable groups of the parent compound. Of particular interest are compounds modified at a carboxyl group, a hydroxyl group, or an amino group. Examples of suitable derivatives are esters or amides.

The chemical compound of the invention may be provided in dissoluble or indissoluble forms together with a pharmaceutically acceptable solvent such as water, ethanol, and the like. Dissoluble forms may also include hydrated forms such as the monohydrate, the dihydrate, the hemihydrate, the trihydrate, the tetrahydrate, and the like. In general, the dissoluble forms are considered equivalent to indissoluble forms for the purposes of this invention.

Steric Isomers

It will be appreciated by those skilled in the art that the compounds of the present invention exist in different stereoisomeric forms - including enantiomers, diastereomers and cis-trans-isomers.

The invention includes all such isomers and any mixtures thereof including racemic mixtures.

Racemic forms can be resolved into the optical antipodes by known methods and techniques. One way of separating the enantiomeric compounds (including enantiomeric intermediates) is - in the case the compound being a chiral acid - by use of an optically active amine, and liberating the diastereomeric, resolved salt by treatment with an acid. Another method for resolving racemates into the optical antipodes is based upon chromatography on an optical active matrix. Racemic
compounds of the present invention can thus be resolved into their optical antipodes, e.g., by fractional crystallisation of D- or L- (tartrates, mandelates, or camphorsulphonate) salts for example.

The chemical compounds of the present invention may also be resolved by the formation of diastereomeric amides by reaction of the chemical compounds of the present invention with an optically active activated carboxylic acid such as that derived from (+) or (-) phenylalanine, (+) or (-) phenylglycine, (+) or (-) camphalic acid or by the formation of diastereomeric carbamates by reaction of the chemical compound of the present invention with an optically active chloroformate or the like.


Optical active compounds can also be prepared from optical active starting materials or intermediates.

**Labelled Compounds**

The compounds of the invention may be used in their labelled or unlabelled form. In the context of this invention the labelled compound has one or more atoms replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. The labelling will allow easy quantitative detection of said compound.

The labelled compounds of the invention may be useful as diagnostic tools, radio tracers, or monitoring agents in various diagnostic methods, and for in vivo receptor imaging.

The labelled isomer of the invention preferably contains at least one radio-nuclide as a label. Positron emitting radionuclides are all candidates for usage. In the context of this invention the radionuclide is preferably selected from $^{2}$H (deuterium), $^{3}$H (tritium), $^{13}$C, $^{14}$C, $^{131}$I, $^{125}$I, $^{123}$I, and $^{18}$F.

The physical method for detecting the labelled isomer of the present invention may be selected from Position Emission Tomography (PET), Single Photon Imaging Computed Tomography (SPECT), Magnetic Resonance Spectroscopy (MRS), Magnetic Resonance Imaging (MRI), and Computed Axial X-ray Tomography (CAT), or combinations thereof.

**Methods of Preparation**

The chemical compounds of the invention may be prepared by conventional methods for chemical synthesis, e.g. those described in the working examples. The starting materials for the processes described in the present application are known or
may readily be prepared by conventional methods from commercially available chemicals.

Also one compound of the invention can be converted to another compound of the invention using conventional methods.

The end products of the reactions described herein may be isolated by conventional techniques, e.g. by extraction, crystallisation, distillation, chromatography, etc.

**Biological Activity**

Compounds of the invention may be tested for their ability to inhibit reuptake of the monoamines dopamine, noradrenaline and serotonin in synaptosomes e.g. such as described in WO 97/30997. Based on the balanced activity observed in these tests the compound of the invention is considered useful for the treatment, prevention or alleviation of a disease or a disorder or a condition of a mammal, including a human, which disease, disorder or condition is responsive to inhibition of monoamine neurotransmitter re-uptake in the central nervous system.

In a special embodiment, the compounds of the invention are considered useful for the treatment, prevention or alleviation of: mood disorder, depression, atypical depression, depression secondary to pain, major depressive disorder, dysthymic disorder, bipolar disorder, bipolar I disorder, bipolar II disorder, cyclothymic disorder, mood disorder due to a general medical condition, substance-induced mood disorder, pseudodementia, Ganser's syndrome, obsessive compulsive disorder, panic disorder, panic disorder without agoraphobia, panic disorder with agoraphobia, agoraphobia without history of panic disorder, panic attack, memory deficits, memory loss, attention deficit hyperactivity disorder, obesity, anxiety, generalized anxiety disorder, eating disorder, Parkinson's disease, parkinsonism, dementia, dementia of ageing, senile dementia, Alzheimer's disease, acquired immunodeficiency syndrome dementia complex, memory dysfunction in ageing, specific phobia, social phobia, social anxiety disorder, post-traumatic stress disorder, acute stress disorder, drug addiction, drug abuse, cocaine abuse, nicotine abuse, tobacco abuse, alcohol addiction, alcoholism, kleptomania, pain, chronic pain, inflammatory pain, neuropathic pain, migraine pain, tension-type headache, chronic tension-type headache, pain associated with depression, fibromyalgia, arthritis, osteoarthritis, rheumatoid arthritis, back pain, cancer pain, irritable bowel pain, irritable bowel syndrome, post-operative pain, post-mastectomy pain syndrome (PMPS), post-stroke pain, drug-induced neuropathy, diabetic neuropathy, sympathetically-maintained pain, trigeminal neuralgia, dental pain, myofacial pain, phantom-limb pain, bulimia, premenstrual syndrome, premenstrual dysphoric disorder, late luteal phase syndrome, post-traumatic syndrome, chronic fatigue syndrome, urinary incontinence, stress incontinence, urge incontinence,
nocturnal incontinence, sexual dysfunction, premature ejaculation, erectile difficulty, erectile dysfunction, premature female orgasm, restless leg syndrome, periodic limb movement disorder, eating disorders, anorexia nervosa, sleep disorders, pervasive developmental disorders, autism, Asperger's disorder, Rett's disorder, childhood disintegrative disorder, learning disabilities, motor skills disorders, mutism, trichotillomania, narcolepsy, post-stroke depression, stroke-induced brain damage, stroke-induced neuronal damage, Gilles de la Tourette's disease, tinnitus, tic disorders, body dysmorphic disorders, oppositional defiant disorder or post-stroke disabilities. In a preferred embodiment, the compounds are considered useful for the treatment, prevention or alleviation of depression.

It is at present contemplated that a suitable dosage of the active pharmaceutical ingredient (API) is within the range of from about 0.1 to about 1000 mg API per day, more preferred of from about 10 to about 500 mg API per day, most preferred of from about 30 to about 100 mg API per day, dependent, however, upon the exact mode of administration, the form in which it is administered, the indication considered, the subject and in particular the body weight of the subject involved, and further the preference and experience of the physician or veterinarian in charge.

Preferred compounds of the invention show a biological activity in the sub-micromolar and micromolar range, i.e. of from below 1 to about 100 µM.

**Pharmaceutical Compositions**

In another aspect the invention provides novel pharmaceutical compositions comprising a therapeutically effective amount of the chemical compound of the invention.

While a chemical compound of the invention for use in therapy may be administered in the form of the raw chemical compound, it is preferred to introduce the active ingredient, optionally in the form of a physiologically acceptable salt, in a pharmaceutical composition together with one or more adjuvants, excipients, carriers, buffers, diluents, and/or other customary pharmaceutical auxiliaries.

In a preferred embodiment, the invention provides pharmaceutical compositions comprising the chemical compound of the invention, or a pharmaceutically acceptable salt or derivative thereof, together with one or more pharmaceutically acceptable carriers, and, optionally, other therapeutic and/or prophylactic ingredients, known and used in the art. The carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not harmful to the recipient thereof.

Pharmaceutical compositions of the invention may be those suitable for oral, rectal, bronchial, nasal, pulmonal, topical (including buccal and sub-lingual), transdermal, vaginal or parenteral (including cutaneous, subcutaneous, intramuscular, intraperitoneal, intravenous, intraarterial, intracerebral, intraocular injection or infusion) administration, or
those in a form suitable for administration by inhalation or insufflation, including powders and liquid aerosol administration, or by sustained release systems. Suitable examples of sustained release systems include semipermeable matrices of solid hydrophobic polymers containing the compound of the invention, which matrices may be in form of shaped articles, e.g. films or microcapsules.

The chemical compound of the invention, together with a conventional adjuvant, carrier, or diluent, may thus be placed into the form of pharmaceutical compositions and unit dosages thereof. Such forms include solids, and in particular tablets, filled capsules, powder and pellet forms, and liquids, in particular aqueous or non-aqueous solutions, suspensions, emulsions, elixirs, and capsules filled with the same, all for oral use, suppositories for rectal administration, and sterile injectable solutions for parenteral use. Such pharmaceutical compositions and unit dosage forms thereof may comprise conventional ingredients in conventional proportions, with or without additional active compounds or principles, and such unit dosage forms may contain any suitable effective amount of the active ingredient commensurate with the intended daily dosage range to be employed.

The chemical compound of the present invention can be administered in a wide variety of oral and parenteral dosage forms. It will be obvious to those skilled in the art that the following dosage forms may comprise, as the active component, either a chemical compound of the invention or a pharmaceutically acceptable salt of a chemical compound of the invention.

For preparing pharmaceutical compositions from a chemical compound of the present invention, pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. A solid carrier can be one or more substances which may also act as diluents, flavouring agents, solubilizers, lubricants, suspending agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.

In powders, the carrier is a finely divided solid, which is in a mixture with the finely divided active component.

In tablets, the active component is mixed with the carrier having the necessary binding capacity in suitable proportions and compacted in the shape and size desired.

The powders and tablets preferably contain from five or ten to about seventy percent of the active compound. Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like. The term "preparation" is intended to include the formulation of the active compound with encapsulating material as carrier providing a capsule in which the active component, with or without carriers, is surrounded by a carrier, which is thus in association with it. Similarly,
cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid forms suitable for oral administration.

For preparing suppositories, a low melting wax, such as a mixture of fatty acid glyceride or cocoa butter, is first melted and the active component is dispersed homogeneously therein, as by stirring. The molten homogenous mixture is then poured into convenient sized moulds, allowed to cool, and thereby to solidify.

Compositions suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or sprays containing in addition to the active ingredient such carriers as are known in the art to be appropriate.

Liquid preparations include solutions, suspensions, and emulsions, for example, water or water-propylene glycol solutions. For example, parenteral injection liquid preparations can be formulated as solutions in aqueous polyethylene glycol solution.

The chemical compound according to the present invention may thus be formulated for parenteral administration (e.g. by injection, for example bolus injection or continuous infusion) and may be presented in unit dose form in ampoules, pre-filled syringes, small volume infusion or in multi-dose containers with an added preservative. The compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulation agents such as suspending, stabilising and/or dispersing agents. Alternatively, the active ingredient may be in powder form, obtained by aseptic isolation of sterile solid or by lyophilization from solution, for constitution with a suitable vehicle, e.g. sterile, pyrogen-free water, before use.

Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavours, stabilising and thickening agents, as desired.

Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, or other well known suspending agents.

Also included are solid form preparations, intended for conversion shortly before use to liquid form preparations for oral administration. Such liquid forms include solutions, suspensions, and emulsions. In addition to the active component such preparations may comprise colorants, flavours, stabilisers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.

For topical administration to the epidermis the chemical compound of the invention may be formulated as ointments, creams or lotions, or as a transdermal patch. Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents. Lotions may be formulated with an aqueous or oily base and will in general also contain one or more emulsifying agents,
stabilising agents, dispersing agents, suspending agents, thickening agents, or colouring agents.

Compositions suitable for topical administration in the mouth include lozenges comprising the active agent in a flavoured base, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert base such as gelatin and glycerine or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.

Solutions or suspensions are applied directly to the nasal cavity by conventional means, for example with a dropper, pipette or spray. The compositions may be provided in single or multi-dose form.

Administration to the respiratory tract may also be achieved by means of an aerosol formulation in which the active ingredient is provided in a pressurised pack with a suitable propellant such as a chlorofluorocarbon (CFC) for example dichlorodifluoromethane, trichlorofluoromethane, or dichlorotetrafluoroethane, carbon dioxide, or other suitable gas. The aerosol may conveniently also contain a surfactant such as lecithin. The dose of drug may be controlled by provision of a metered valve.

Alternatively the active ingredients may be provided in the form of a dry powder, for example a powder mix of the compound in a suitable powder base such as lactose, starch, starch derivatives such as hydroxypropylmethyl cellulose and polyvinylpyrrolidone (PVP). Conveniently the powder carrier will form a gel in the nasal cavity. The powder composition may be presented in unit dose form for example in capsules or cartridges of, e.g., gelatin, or blister packs from which the powder may be administered by means of an inhaler.

In compositions intended for administration to the respiratory tract, including intranasal compositions, the compound will generally have a small particle size for example of the order of 5 microns or less. Such a particle size may be obtained by means known in the art, for example by micronization.

When desired, compositions adapted to give sustained release of the active ingredient may be employed.

The pharmaceutical preparations are preferably in unit dosage forms. In such form, the preparation is subdivided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packaged tablets, capsules, and powders in vials or ampoules. Also, the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.

Tablets or capsules for oral administration and liquids for intravenous administration and continuous infusion are preferred compositions.
Further details on techniques for formulation and administration may be found in the latest edition of *Remington's Pharmaceutical Sciences* (Maack Publishing Co., Easton, PA).

A therapeutically effective dose refers to that amount of active ingredient, which ameliorates the symptoms or condition. Therapeutic efficacy and toxicity, e.g. ED$_{50}$ and LD$_{50}$, may be determined by standard pharmacological procedures in cell cultures or experimental animals. The dose ratio between therapeutic and toxic effects is the therapeutic index and may be expressed by the ratio LD$_{50}$/ED$_{50}$. Pharmaceutical compositions exhibiting large therapeutic indexes are preferred.

The dose administered must of course be carefully adjusted to the age, weight and condition of the individual being treated, as well as the route of administration, dosage form and regimen, and the result desired, and the exact dosage should of course be determined by the practitioner.

The actual dosage depends on the nature and severity of the disease being treated, and is within the discretion of the physician, and may be varied by titration of the dosage to the particular circumstances of this invention to produce the desired therapeutic effect. However, it is presently contemplated that pharmaceutical compositions containing of from about 0.1 to about 500 mg of active ingredient per individual dose, preferably of from about 1 to about 100 mg, most preferred of from about 1 to about 10 mg, are suitable for therapeutic treatments.

The active ingredient may be administered in one or several doses per day. A satisfactory result can, in certain instances, be obtained at a dosage as low as 0.1 µg/kg i.v. and 1 µg/kg p.o. The upper limit of the dosage range is presently considered to be about 10 mg/kg i.v. and 100 mg/kg p.o. Preferred ranges are from about 0.1 µg/kg to about 10 mg/kg/day i.v., and from about 1 µg/kg to about 100 mg/kg/day p.o.

**Methods of Therapy**

In another aspect the invention provides a method for the treatment, prevention or alleviation of a disease or a disorder or a condition of a living animal body, including a human, which disease, disorder or condition is responsive to inhibition of monoamine neurotransmitter re-uptake in the central nervous system, and which method comprises administering to such a living animal body, including a human, in need thereof an effective amount of a chemical compound of the invention.

It is at present contemplated that suitable dosage ranges are 0.1 to 1000 milligrams daily, 10-500 milligrams daily, and especially 30-100 milligrams daily, dependent as usual upon the exact mode of administration, form in which administered, the indication toward which the administration is directed, the subject involved and the body weight of the subject involved, and further the preference and experience of the physician or veterinarian in charge.
EXAMPLES

The invention is further illustrated with reference to the following examples, which are not intended to be in any way limiting to the scope of the invention as claimed.

**General**: All reactions involving air sensitive reagents or intermediates were performed under nitrogen or argon and in anhydrous solvents.

9-Oxo-S-aza-spiroδ.δUndecane-S-carboxylic acid benzyl ester


To a solution of 9-oxo-S-aza-spiro δ.δUndecane-S-carboxylic acid benzyl ester (6.22 g, 20.8 mmol), di-tert-butyl dicarbonate (6.81 g, 31.2 mmol) and potassium carbonate (5.75 g, 41.6 mmol) in ethanol/water (9:1, 200 ml), palladium on carbon (221 mg, 2.08 mmol) was added and the mixture stirred under a hydrogen atmosphere overnight. The mixture was filtered over celite and the celite pad was washed with ethanol and ethyl acetate. The filtrate was evaporated to dryness and re-dissolved in ethyl acetate and water. The aqueous phase was extracted twice with ethyl acetate. The combined organic phase was washed with brine, dried (sodium sulfate), filtered and evaporated to give a colourless oil. Flash chromatography (heptane/ethyl acetate 3:1 to 1:1) gave 2.83 g (51%) of 9-oxo-3-aza-spiro[5.5]undecane-3-carboxylic acid tert-butyl ester.

9-Hydroxy-S-aza-spiro5.5.Undecane-S-carboxylic acid tert-butyl ester

9-Oxo-S-aza-spiro δ.δUndecane-S-carboxylic acid tert-butyl ester (1 g, 3.74 mmol) and cerium(III) chloride heptahydrate (1.39 g, 3.74 mmol) in methanol (40 ml) was cooled to -78 °C and sodium borohydride (141 mg, 3.74 mmol) was added in 4 portions. The mixture was warmed up to -20°C and stirred for 30 min. Water was added and the mixture was concentrated *in vacuo*. The aqueous layer was extracted three times with ethyl acetate. The combined organic phase was washed with brine, dried (sodium sulfate), filtered and evaporated to give 883 mg (88%) of 9-hydroxy-3-aza-spiro[5.5]undecane-3-carboxylic acid tert-butyl ester as a colourless oil.
Method A

9-(3,4-Dichloro-phenoxy)-3-aza-spiro[5.5]undecane trifluoroacetic acid salt
Diisopropylazo dicarboxylate (315 mg, 1.56 mmol) in diethyl ether (2 ml) was added slowly to an ice cooled solution of triphenylphosphine (582 mg, 2.22 mmol) in diethyl ether (5 ml). The reaction mixture was stirred for 20 min. 3,4-Dichlorophenol (290 mg, 1.78 mmol) in diethyl ether (2 ml) was added and stirred 30 min at 0°C and 9-hydroxy-3-aza-spiro[5.5]undecane-3-carboxylic acid tert-butyl ester (400 mg, 1.48 mmol) in diethylether (5 ml) was added and the mixture stirred at room temperature over night.

Evaporation followed by flash chromatography (heptane/ethylacetate 9:1) gave 340 mg (56%) of 9-(3,4-dichloro-phenoxy)-3-aza-spiro[5.5]undecane-3-carboxylic acid tert-butyl ester.

9-(3,4-Dichloro-phenoxy)-3-aza-spiro[5.5]undecane-3-carboxylic acid tert-butyl ester (340 mg, 0.82 mmol) was dissolved in dichloromethane (8 ml) and cooled on an ice bath. Trifluoroacetic acid (2 ml) was added and stirred for 2 h at room temperature. Evaporation followed by co-evaporation with toluene and ethyl acetate gave a solid compound. The compound was washed with diethyl ether to give 222 mg (63%) of 9-(3,4-dichloro-phenoxy)-3-aza-spiro[5.5]undecane trifluoroacetic acid salt as a white crystalline compound. Mp. 139.6-141.2°C.

9-(6-Methoxy-Naphthalen-2-yloxy)-3-aza-spiro[5.5]undecane
Was prepared according to method A from 6-methoxy-2-naphthol and 9-hydroxy-3-aza-spiro[5.5]undecane-3-carboxylic acid tert-butyl ester. Mp. 111.8-113.5°C.

7-(3-Aza-spiro[5.5]undec-9-yloxy)-chromen-2-one
Was prepared according to method A from 7-hydroxycoumarin and 9-hydroxy-3-aza-spiro[5.5]undecane-3-carboxylic acid tert-butyl ester. Mp. 126-128°C.

9-(3-Bromo-4-chloro-phenoxy)-3-aza-spiro[5.5]undecane
Is prepared according to method A.

9-(4-Chloro-phenoxy)-3-aza-spiro[5.5]undecane
Was prepared according to method A from 4-chlorophenol and 9-hydroxy-3-aza-spiro[5.5]undecane-3-carboxylic acid tert-butyl ester. Mp. 140-142°C.

9-(4-Chloro-3-fluoro-phenoxy)-3-aza-spiro[5.5]undecane
Is prepared according to method A.
9-(3-Chloro-4-fluoro-phenoxy)-3-aza-spiro[5.5]undecane
Is prepared according to method A.

9-(4-Chloro-3-trifluoromethyl-phenoxy)-3-aza-spiro[5.5]undecane
Is prepared according to method A.

9-(Naphthalen-2-yloxy)-3-aza-spiro[5.5]undecane
Was prepared according to method A from 2-naphthol and 9-hydroxy-3-aza-
spirotδδJundecane-S-carboxylic acid tert-butyl ester. Mp. 132.2-133.8 0C.

6-(3-Aza-spiro[5.5]undec-9-yloxy)-chromen-2-one
Was prepared according to method A from 6-hydroxycoumarin and 9-hydroxy-3-aza-
spiro[5.5]undecane-3-carboxylic acid tert-butyl ester. Mp. 192.9-193.6 0C.

(3-Aza-spiro[5.5]undec-9-yl)-(3,4-dichloro-phenyl)-amine
3,4-Dichloroaniline (364 mg, 2.2 mmol), sodium triacetoxyborohydride (889 mg, 4.20
mmol) and acetic acid (0.24 ml, 4.20 mmol) were added to a solution of 9-oxo-3-aza-
spiro[5.5]undecane-3-carboxylic acid tert-butyl ester (561 mg, 2.10 mmol) in 1,2-
dichloroethane (30 ml) with crunched 4A mol sieves (10 g). The mixture was stirred a
room temperature over night. Additional 4A mol sieves (12 g) and sodium
triacetoxyborohydride (445 mg) was added and the mixture was stirred over night. The
reaction was quenched with water and 5% citric acid was added. The mixture was
filtered through kieselguhr and the filtrated was evaporated until only the aqueous layer
remained. The aqueous layer was extracted with ethyl acetate (3 x 50 ml) and the
combined organic phases were washed with brine, dried with sodium sulphate, filtered
and evaporated to give the crude product. Flash chromatography (ethyl
acetale/heptane) gave 9-(3,4-dichloro-phenylamino)-3-aza-spiro[5.5]undecane-3-
carboxylic acid tert-butyl ester (258 mg, 0.624 mmol, 30%).

To an ice-cooled solution of 9-(3,4-dichloro-phenylamino)-3-aza-spiro[5.5]undecane-3-
carboxylic acid tert-butyl ester (258 mg, 0.624 mmol) in dichloromethane (10 ml) a
solution of trifluoroacetic acid (4 ml) in dichloromethane (5 ml) was added. The
mixture was stirred a room temperature over night. Water was added followed by
sodium hydroxide 3 M to pH 9-10. The aqueous layer was extracted with
dichloromethane (4 x 40 ml). The combined organic layers were washed with brine,
dried with sodium sulphate and evaporated to give (3-aza-spiro[5.5]undec-9-yl)-(3,4-
dichloro-phenyl)-amine (164 mg 84%) as a brownish solid. Mp. 128-132 0C.
9-(3,4-Dichloro-phenoxy)-3-methyl-3-aza-spiro[5.5]undecane

To an ice cooled solution of 9-(3,4-dichloro-phenoxy)-3-aza-spiro[5.5]undecane-3-carboxylic acid tert-butyl ester (60 mg, 0.19 mmol) in dichloroethane (10 ml), formaldehyde (37% in water, 54 µl, 0.72 mmol) was added and stirred for 1 h at 0°C. Sodium triacetoxyborohydride (102 mg, 0.48 mmol) was added and stirred overnight at room temperature. The reaction was quenched with aqueous sodium hydrogen carbonate and evaporated. The remaining aqueous phase was extracted four times with dichloromethane and the combined organic phase was dried (sodium sulfate), filtered and evaporated to give 75 mg (95%) 9-(3,4-dichloro-phenoxy)-3-methyl-3-aza-spiro[5.5]undecane as a yellow oil. LC-ESI-HRMS of [M+H]+ shows 328.1249 Da. Calc. 328.123495 Da, dev. 4.3 ppm.

Test Example

In vitro inhibition activity

A number of compounds were tested for their ability to inhibit the reuptake of the monoamine neurotransmitters dopamine (DA), noradrenaline (NA) and serotonine (5-HT) in synaptosomes as described in WO 97/16451.

The test values are given as IC₅₀ (the concentration (µM) of the test substance which inhibits the specific binding of ³H-DA, ³H-NA, or ³H-5-HT by 50%).

Test results obtained by testing selected compounds of the present invention appear from the below table:

<table>
<thead>
<tr>
<th>Test compound</th>
<th>DA-uptake IC₅₀(µM)</th>
<th>NA-uptake IC₅₀(µM)</th>
<th>5-HT-uptake IC₅₀(µM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>3rd compound of method A; 7-(3-Aza-spiro[5.5]undec-9-yloxy)-chromen-2-one</td>
<td>1.2</td>
<td>0.086</td>
<td>0.0020</td>
</tr>
<tr>
<td>2nd last compound of method A; (3-Aza-spiro[5.5]undec-9-yl)-(3,4-dichloro-phenyl)-amine</td>
<td>0.49</td>
<td>1.0</td>
<td>0.0023</td>
</tr>
</tbody>
</table>
CLAiMS

1. A compound of Formula I:

\[
\begin{array}{c}
R^a \\
\bigg\uparrow \bigg\downarrow \\
\bigg( I \bigg)
\end{array}
\]

any of its isomers or any mixture of its isomers,
or a pharmaceutically acceptable salt thereof;

wherein

- \( R^a \) represents hydrogen or alkyl;
- which alkyl is optionally substituted with one or more substituents independently selected from the group consisting of:
  - halo, trifluoromethyl, trifluoromethoxy, cyano, hydroxy, amino, nitro, alkoxy, cycloalkoxy, alkyl, cycloalkyl, cycloalkylalkyl, alkenyl and alkynyl; and
- \( R^b \) represents an aryl or a heteroaryl group;
- which aryl or heteroaryl group group is optionally substituted with one or more substituents independently selected from the group consisting of:
  - halo, trifluoromethyl, trifluoromethoxy, cyano, hydroxy, alkoxy, cycloalkoxy, alkoxyalkyl, cycloalkoxyalkyl, methylenedioxy, ethylenedioxy, alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, -NR'R'', -(C=O)NR''R'' or -NR'(C=O)R';
  - wherein \( R' \) and \( R'' \) independent of each other are hydrogen or alkyl
- \( X \) represents -O- or -NR C ;
- wherein \( R^c \) represents hydrogen or alkyl.

2. The compound of claim 1, wherein

- \( R^a \) represents hydrogen or alkyl.

3. The compound of claims 1 or 2, wherein

- \( R^b \) represents a phenyl group,
- which phenyl group is optionally substituted with one or more substituents independently selected from the group consisting of:
  - halo, trifluoromethyl, trifluoromethoxy, cyano and alkoxy.

4. The compound of claims 1 or 2, wherein

- \( R^b \) represents a phenyl group,
which phenyl group is substituted once or twice with substituents independently selected from the group consisting of:
- halo, trifluoromethyl, trifluoromethoxy, cyano and alkoxy.

5. The compound of claims 1 or 2, wherein 
   \( R^b \) represents a naphthyl group, 
   which naphthyl group is optionally substituted with one or more substituents independently selected from the group consisting of:
   - halo, trifluoromethyl, trifluoromethoxy, cyano and alkoxy.

6. The compound of claims 1 or 2, wherein \( R^b \) represents an optionally substituted coumarinyl group.

7. The compound of any one of claims 1-6, wherein X represents -O- or -NH-.

8. The compound of claim 1, which is
   - 9-(3,4-Dichloro-phenoxy)-3-aza-spiro[5.5]undecane;
   - 9-(6-Methoxy-naphthalen-2-yloxy)-3-aza-spiro[5.5]undecane;
   - 7-(3-Aza-spiro[5.5]undec-9-yloxy)-chromen-2-one;
   9-(3-Bromo-4-chloro-phenoxy)-3-aza-spiro[5.5]undecane;
   9-(4-Chloro-phenoxy)-3-aza-spiro[5.5]undecane;
   9-(4-Chloro-3-fluoro-phenoxy)-3-aza-spiro[5.5]undecane;
   9-(3-Chloro-4-fluoro-phenoxy)-3-aza-spiro[5.5]undecane;
   9-(4-Chloro-3-trifluoromethyl-phenoxy)-3-aza-spiro[5.5]undecane;
   9-(Naphthalen-2-yloxy)-3-aza-spiro[5.5]undecane;
   6-(3-Aza-spiro[5.5]undec-9-yloxy)-chromen-2-one;
   (3-Aza-spiro[5.5]undec-9-yl)-(3,4-dichloro-phenyl)-amine;
   9-(3,4-Dichloro-phenoxy)-3-methyl-3-aza-spiro[5.5]undecane;
   or a pharmaceutically acceptable salt thereof.

9. A pharmaceutical composition, comprising a therapeutically effective amount of a compound of any one of claims 1-8, any of its isomers or any mixture of its isomers, or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, excipient or diluent.

10. Use of a compound of any of claims 1-8, any of its isomers or any mixture of its isomers, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament.
11. The use according to claim 10, for the manufacture of a pharmaceutical
pharmaceutical composition for the treatment, prevention or alleviation of a
disease or a disorder or a condition of a mammal, including a human, which
disease, disorder or condition is responsive to inhibition of monoamine
neurotransmitter re-uptake in the central nervous system.

12. The use according to claim 11, wherein the disease, disorder or condition is
mood disorder, depression, atypical depression, depression secondary to pain,
major depressive disorder, dysthymic disorder, bipolar disorder, bipolar II disorder,
bipolar II disorder, cyclothymic disorder, mood disorder due to a general medical
condition, substance-induced mood disorder, pseudodementia, Ganser’s
syndrome, obsessive compulsive disorder, panic disorder, panic disorder without
agoraphobia, panic disorder with agoraphobia, agoraphobia without history of
panic disorder, panic attack, memory deficits, memory loss, attention deficit
hyperactivity disorder, obesity, anxiety, generalized anxiety disorder, eating
disorder, Parkinson’s disease, parkinsonism, dementia, dementia of ageing,
senile dementia, Alzheimer’s disease, acquired immunodeficiency syndrome
dementia complex, memory dysfunction in ageing, specific phobia, social phobia,
social anxiety disorder, post-traumatic stress disorder, acute stress disorder, drug
addiction, drug abuse, cocaine abuse, nicotine abuse, tobacco abuse, alcohol
addiction, alcoholism, kleptomania, pain, chronic pain, inflammatory pain,
neuropathic pain, migraine pain, tension-type headache, chronic tension-type
headache, pain associated with depression, fibromyalgia, arthritis, osteoarthritis,
rheumatoid arthritis, back pain, cancer pain, irritable bowel pain, irritable bowel
syndrome, post-operative pain, post-mastectomy pain syndrome (PMPS), post-
stroke pain, drug-induced neuropathy, diabetic neuropathy, sympathetically-
maintained pain, trigeminal neuralgia, dental pain, myofacial pain, phantom-limb
pain, bulimia, premenstrual syndrome, premenstrual dysphoric disorder, late
luteal phase syndrome, post-traumatic syndrome, chronic fatigue syndrome,
urinary incontinence, stress incontinence, urge incontinence, nocturnal
incontinence, sexual dysfunction, premature ejaculation, erectile difficulty, erectile
dysfunction, premature female orgasm, restless leg syndrome, periodic limb
movement disorder, eating disorders, anorexia nervosa, sleep disorders,
pervasive developmental disorders, autism, Asperger’s disorder, Rett’s disorder,
childhood disintegrative disorder, learning disabilities, motor skills disorders,
mutism, trichotillomania, narcolepsy, post-stroke depression, stroke-induced brain
damage, stroke-induced neuronal damage, Gilles de la Tourette’s disease,
tinnitus, tic disorders, body dysmorphic disorders, oppositional defiant disorder or
post-stroke disabilities.
13. A method for treatment, prevention or alleviation of a disease or a disorder or a condition of a living animal body, including a human, which disorder, disease or condition is responsive to inhibition of monoamine neurotransmitter re-uptake in the central nervous system, which method comprises the step of administering to such a living animal body in need thereof a therapeutically effective amount of a compound according to any one of the claims 1-8, any of its isomers or any mixture of its isomers, or a pharmaceutically acceptable salt thereof.
INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2006/063634

A. CLASSIFICATION OF SUBJECT MATTER

INV. C07D221/20 C07D491/10 A61K31/438 A61P25/00

According to international Patent Classification (IPC) and/or national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical search terms used)
EPO-Internal, WPI Data, CHEM ABS Data, BEILSTEIN Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication of where appropriate of the relevant passages</th>
<th>Relevant to claim</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>WO 97/30997 A (NEUROSEARCH AS [DK]; SCHEEL KRUEGER JOERGFJ [DK]; MOLDT PETER [DK], WA) 28 August 1997 (1997-08-28) cited in the application claims 1,5</td>
<td>1,9, 10, 13</td>
</tr>
</tbody>
</table>

D. Further documents are listed in the continuation of Box C

X See patent family annex

* Special categories of cited documents

A: document defining the general state of the art which is not considered to be of particular relevance
E: earlier document but published on or after the international filing date
L: document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
O: document referring to an oral disclosure, use, exhibition or other means
P: document published prior to the international filing date but later than the priority date claimed

T: later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
X: document of particular relevance the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
Y: document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
Z: document member of the same patent family

Date of the actual completion of the international search
30 October 2006

Date of mailing of the international search report
08/11/2006

Name and mailing address of the ISA/
European Patent Office
P B 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel (+31-70) 340-2040, TX 31 651 epo nl
Fax (+31-70) 340-3016

Authorized officer
Menchaca, Roberto
This International Search Report has not been established in respect of certain claims under Article 17(2)a) for the following reasons.

### Box II  Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

1. [X] Claims Nos because they relate to subject matter not required to be searched by this Authority, namely:
   Although claim 13 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

2. [ ] Claims Nos because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. [ ] Claims Nos because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6 4(a)

### Box III  Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows.

1. [X] As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. [ ] As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. [ ] As only some of the required additional search fees were timely paid by the applicant, this International Search Report

4. [ ] No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims, it is covered by claims Nos

Remark on Protest
- [ ] The additional search fees were accompanied by the applicant's protest
- [ ] No protest accompanied the payment of additional search fees
<table>
<thead>
<tr>
<th>Patent document cited in search report</th>
<th>publication date</th>
<th>Patent family member(s)</th>
<th>Publication date</th>
</tr>
</thead>
<tbody>
<tr>
<td>wo 9730997 A</td>
<td>28-08-1997</td>
<td>AT 203023 T</td>
<td>15-07-2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 720358 B2</td>
<td>01-06-2000</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 1794097 A</td>
<td>10-09-1997</td>
</tr>
<tr>
<td></td>
<td></td>
<td>BG 63945 B1</td>
<td>31-07-2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>BG 102637 A</td>
<td>30-06-1999</td>
</tr>
<tr>
<td></td>
<td></td>
<td>BR 9707636 A</td>
<td>27-07-1999</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2244773 A1</td>
<td>28-08-1997</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CN 1211982 A</td>
<td>24-03-1999</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CZ 9802520 A3</td>
<td>11-11-1998</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DE 69705608 D1</td>
<td>16-08-2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DE 69705608 T2</td>
<td>16-05-2002</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DK 0885220 T3</td>
<td>15-10-2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EE 9800254 A</td>
<td>15-02-1999</td>
</tr>
<tr>
<td></td>
<td></td>
<td>GR 3036829 T3</td>
<td>31-01-2002</td>
</tr>
<tr>
<td></td>
<td></td>
<td>HK 1018957 A1</td>
<td>27-09-2002</td>
</tr>
<tr>
<td></td>
<td></td>
<td>HU 9901199 A2</td>
<td>30-08-1999</td>
</tr>
<tr>
<td></td>
<td></td>
<td>IL 125146 A</td>
<td>10-03-2002</td>
</tr>
<tr>
<td></td>
<td></td>
<td>IS 4825 A</td>
<td>17-08-1998</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 3238414 B2</td>
<td>17-12-2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2000504739 T</td>
<td>18-04-2000</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NO 318731 B1</td>
<td>02-05-2005</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NZ 330886 A</td>
<td>25-02-1999</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PL 328503 A1</td>
<td>01-02-1999</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PT 885220 T</td>
<td>30-11-2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>RU 2167876 C2</td>
<td>27-05-2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SG 99853 A1</td>
<td>27-11-2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SK 92998 A3</td>
<td>04-11-1998</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TR 9801641 T2</td>
<td>23-11-1998</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 6288079 B1</td>
<td>11-09-2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ZA 9701525 A</td>
<td>21-10-1997</td>
</tr>
</tbody>
</table>